JP7331322B2 - 新規の送達系 - Google Patents
新規の送達系 Download PDFInfo
- Publication number
- JP7331322B2 JP7331322B2 JP2020518603A JP2020518603A JP7331322B2 JP 7331322 B2 JP7331322 B2 JP 7331322B2 JP 2020518603 A JP2020518603 A JP 2020518603A JP 2020518603 A JP2020518603 A JP 2020518603A JP 7331322 B2 JP7331322 B2 JP 7331322B2
- Authority
- JP
- Japan
- Prior art keywords
- delivery system
- coating
- inner coating
- solid core
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000576 coating method Methods 0.000 claims description 46
- 239000011248 coating agent Substances 0.000 claims description 43
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 23
- 239000007787 solid Substances 0.000 claims description 19
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 14
- 229960002477 riboflavin Drugs 0.000 claims description 14
- 229920000615 alginic acid Polymers 0.000 claims description 12
- 235000010443 alginic acid Nutrition 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 229940088594 vitamin Drugs 0.000 claims description 8
- 229930003231 vitamin Natural products 0.000 claims description 8
- 235000013343 vitamin Nutrition 0.000 claims description 8
- 239000011782 vitamin Substances 0.000 claims description 8
- 229920001222 biopolymer Polymers 0.000 claims description 7
- 239000001814 pectin Substances 0.000 claims description 7
- 229920001277 pectin Polymers 0.000 claims description 7
- 210000000813 small intestine Anatomy 0.000 claims description 7
- 229920001800 Shellac Polymers 0.000 claims description 6
- 229930003471 Vitamin B2 Natural products 0.000 claims description 6
- 235000010987 pectin Nutrition 0.000 claims description 6
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 6
- 239000004208 shellac Substances 0.000 claims description 6
- 229940113147 shellac Drugs 0.000 claims description 6
- 235000013874 shellac Nutrition 0.000 claims description 6
- 235000019164 vitamin B2 Nutrition 0.000 claims description 6
- 239000011716 vitamin B2 Substances 0.000 claims description 6
- 229910001424 calcium ion Inorganic materials 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- 239000003925 fat Substances 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 229940097362 cyclodextrins Drugs 0.000 claims description 2
- 239000002245 particle Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 239000011247 coating layer Substances 0.000 description 11
- 229940072056 alginate Drugs 0.000 description 10
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000002775 capsule Substances 0.000 description 8
- 235000019192 riboflavin Nutrition 0.000 description 8
- 239000002151 riboflavin Substances 0.000 description 8
- 210000002429 large intestine Anatomy 0.000 description 7
- 239000013543 active substance Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 238000005538 encapsulation Methods 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 239000002417 nutraceutical Substances 0.000 description 5
- 235000021436 nutraceutical agent Nutrition 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 235000005985 organic acids Nutrition 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 4
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 4
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 4
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 4
- 239000003431 cross linking reagent Substances 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 229940045109 genistein Drugs 0.000 description 4
- 235000006539 genistein Nutrition 0.000 description 4
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 4
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 4
- 229940093915 gynecological organic acid Drugs 0.000 description 4
- 150000004668 long chain fatty acids Chemical class 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 4
- 229940012843 omega-3 fatty acid Drugs 0.000 description 4
- 239000006014 omega-3 oil Substances 0.000 description 4
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 4
- 229940033080 omega-6 fatty acid Drugs 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- 235000013406 prebiotics Nutrition 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 235000021283 resveratrol Nutrition 0.000 description 4
- 229940016667 resveratrol Drugs 0.000 description 4
- 235000021391 short chain fatty acids Nutrition 0.000 description 4
- 235000019156 vitamin B Nutrition 0.000 description 4
- 239000011720 vitamin B Substances 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- 239000004971 Cross linker Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000112 colonic effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 150000004666 short chain fatty acids Chemical class 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 241000605980 Faecalibacterium prausnitzii Species 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 239000007931 coated granule Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010924 continuous production Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229960000292 pectin Drugs 0.000 description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical class OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229920001688 coating polymer Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- NSNHWTBQMQIDCF-UHFFFAOYSA-N dihydrate;hydrochloride Chemical compound O.O.Cl NSNHWTBQMQIDCF-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010034 metabolic health Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
- A23K40/30—Shaping or working-up of animal feeding-stuffs by encapsulating; by coating
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
- A23P20/10—Coating with edible coatings, e.g. with oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
- A23P20/10—Coating with edible coatings, e.g. with oils or fats
- A23P20/105—Coating with compositions containing vegetable or microbial fermentation gums, e.g. cellulose or derivatives; Coating with edible polymers, e.g. polyvinyalcohol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/06—Making microcapsules or microballoons by phase separation
- B01J13/14—Polymerisation; cross-linking
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/7044—Vitamin B2
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Animal Husbandry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- General Preparation And Processing Of Foods (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
(a)少なくとも1つの水溶性ビタミン(特に、ビタミンB2)を含む固体コアと、
(b)架橋された少なくとも1つの発酵性バイオポリマーを含む内側コーティングと、
(c)胃条件に対して耐性があり、且つ小腸において放出性である外側コーティングと
からなる。
第1のステップでは、スプレー乾燥プロセスによって固体コアが製造され、第2のステップでは、スプレーコーティングによって固体コア(第1のステップで得られる)が内側コーティングのコーティング材料でコーティングされ、次に架橋剤が粒子上に噴霧される。第3のステップでは、前述のステップで得られた粒子上に外側コーティングが噴霧され、最後に粒子が乾燥される。
[実施例1:]
12gのアルギン酸Na(grinstedアルギン酸ナトリウム)を568gの水中に50℃で攪拌しながら溶解させた。1.5gの塩化Ca二水和物を148.5gの水中に溶解させた。80gの粒状リボフラビン(B2 Universal、DSM)を流動床処理装置(WFP mini、DMR、Wurster構成)に充填した。全てのコーティングステップを約40℃の製品温度で実施した。まずアルギネート溶液を流動化リボフラビン粒上に噴霧した。アルギネート溶液を噴霧した後、補給チューブを水で簡単に洗浄した。塩化Ca溶液を40℃で硬化のために内側コーティング上に噴霧した。溶液を硬化させた後、固形分が25%の117gの水性シェラック調製物(Aquagold SSB、Stroever)を外側コーティングとして噴霧した。シェラックを噴霧した後、流動床で製品を乾燥させた。103gのコーティングされた顆粒が得られた。
Claims (7)
- (a)少なくとも1つの水溶性ビタミンを含む固体コアと、
(b)架橋された少なくとも1つの発酵性バイオポリマーを含む内側コーティングと、
(c)胃条件に対して耐性があり、且つ小腸において放出性である外側コーティングと
からなる送達系であって、
前記発酵性バイオポリマーは、アルギネート、ペクチン、シクロデキストリン及び他のガムからなる群から選択され、
前記外側コーティングは、シェラック、メタクリレートコポリマー及び脂肪からなる群から選択され、
前記固体コアは、前記送達系の全重量を基準として50~85重量%であり、
前記内側コーティングは、前記送達系の全重量を基準として1~20重量%であり、
前記外側コーティングは、前記送達系の全重量を基準として1~30重量%である、送達系。 - 前記固体コアがビタミンB2を含む、請求項1に記載の送達系。
- 前記内側コーティングがMg及び/又はCaイオンで架橋されている、請求項1又は2に記載の送達系。
- バッチ式で実行される、請求項1~3のいずれか一項に記載の送達系の製造方法。
- 連続的に実行される、請求項1~3のいずれか一項に記載の送達系の製造方法。
- 請求項1~3のいずれか一項に記載の少なくとも1つの送達系を用いた、プレミックスの製造方法。
- 請求項1~3のいずれか一項に記載の少なくとも1つの送達系を含むプレミックス。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17199806 | 2017-11-03 | ||
EP17199806.5 | 2017-11-03 | ||
PCT/EP2018/079662 WO2019086425A1 (en) | 2017-11-03 | 2018-10-30 | New delivery system |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021501676A JP2021501676A (ja) | 2021-01-21 |
JP7331322B2 true JP7331322B2 (ja) | 2023-08-23 |
Family
ID=60473269
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020518607A Active JP7331323B2 (ja) | 2017-11-03 | 2018-10-30 | 新規の送達系 |
JP2020518603A Active JP7331322B2 (ja) | 2017-11-03 | 2018-10-30 | 新規の送達系 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020518607A Active JP7331323B2 (ja) | 2017-11-03 | 2018-10-30 | 新規の送達系 |
Country Status (7)
Country | Link |
---|---|
US (2) | US11872316B2 (ja) |
EP (2) | EP3703514A1 (ja) |
JP (2) | JP7331323B2 (ja) |
KR (2) | KR20200084329A (ja) |
CN (2) | CN111315237A (ja) |
BR (2) | BR112020008587A2 (ja) |
WO (2) | WO2019086425A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022530314A (ja) * | 2019-04-30 | 2022-06-29 | ディーエスエム アイピー アセッツ ビー.ブイ. | 特定の水溶性ビタミンのための新規な送達システム |
US20220192998A1 (en) * | 2019-04-30 | 2022-06-23 | Dsm Ip Assets B.V. | New delivery system for polyunsaturated fatty acids |
WO2021105040A1 (en) * | 2019-11-27 | 2021-06-03 | Dsm Ip Assets B.V. | Multiple unit pellet system tablet comprising riboflavin |
JP2023503542A (ja) * | 2019-11-27 | 2023-01-31 | ディーエスエム アイピー アセッツ ビー.ブイ. | リボフラビンを含むmups錠剤 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004018443A (ja) | 2002-06-14 | 2004-01-22 | Pigeon Corp | 腸溶性カプセル剤 |
JP2004123636A (ja) | 2002-10-03 | 2004-04-22 | Nof Corp | 二重被覆造粒物およびその製造方法 |
JP2014058502A (ja) | 2012-08-23 | 2014-04-03 | Nisshin Pharma Inc | キトサン含有組成物及びキトサンコーティング組成物 |
JP2014139200A (ja) | 2012-12-21 | 2014-07-31 | Nisshin Pharma Inc | 大腸送達カプセル及びその製造方法 |
JP2017532050A (ja) | 2014-12-09 | 2017-11-02 | インターコンチネンタル グレート ブランズ エルエルシー | 腸溶性被覆機能性食品成分及び腸溶性被覆機能性食品成分の製造方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11744803B2 (en) * | 2005-07-29 | 2023-09-05 | Stichting Groningen Centre for Drug Rese | PH-controlled pulsatile delivery system, methods for preparation and use thereof |
JPWO2008117814A1 (ja) * | 2007-03-26 | 2010-07-15 | 帝國製薬株式会社 | 大腸送達用経口製剤 |
CA2700426C (en) * | 2007-09-25 | 2017-10-31 | Galia Temtsin Krayz | Compositions comprising lipophilic active compounds and method for their preparation |
JP2011504171A (ja) * | 2007-11-13 | 2011-02-03 | ハーキュリーズ・インコーポレーテッド | 栄養補助食品および医薬品の剤形のための水分散性腸溶性コーティング配合物 |
CA2805445C (en) | 2010-07-29 | 2018-05-01 | Cosmo Technologies Ltd. | Pharmaceutical and/or dietary compositions based on short chain fatty acids |
EP2914135A1 (en) | 2012-11-01 | 2015-09-09 | Rijksuniversiteit Groningen | Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract |
JP6660372B2 (ja) * | 2014-08-07 | 2020-03-11 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 送達システム |
-
2018
- 2018-10-30 US US16/761,053 patent/US11872316B2/en active Active
- 2018-10-30 CN CN201880071125.XA patent/CN111315237A/zh active Pending
- 2018-10-30 BR BR112020008587-1A patent/BR112020008587A2/pt unknown
- 2018-10-30 EP EP18795592.7A patent/EP3703514A1/en active Pending
- 2018-10-30 EP EP18795593.5A patent/EP3703515A1/en active Pending
- 2018-10-30 BR BR112020008194-9A patent/BR112020008194A2/pt active IP Right Grant
- 2018-10-30 JP JP2020518607A patent/JP7331323B2/ja active Active
- 2018-10-30 WO PCT/EP2018/079662 patent/WO2019086425A1/en unknown
- 2018-10-30 KR KR1020207014377A patent/KR20200084329A/ko not_active Application Discontinuation
- 2018-10-30 US US16/761,096 patent/US11602503B2/en active Active
- 2018-10-30 JP JP2020518603A patent/JP7331322B2/ja active Active
- 2018-10-30 WO PCT/EP2018/079665 patent/WO2019086427A1/en unknown
- 2018-10-30 CN CN201880071097.1A patent/CN111315236A/zh active Pending
- 2018-10-30 KR KR1020207014379A patent/KR20200084330A/ko not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004018443A (ja) | 2002-06-14 | 2004-01-22 | Pigeon Corp | 腸溶性カプセル剤 |
JP2004123636A (ja) | 2002-10-03 | 2004-04-22 | Nof Corp | 二重被覆造粒物およびその製造方法 |
JP2014058502A (ja) | 2012-08-23 | 2014-04-03 | Nisshin Pharma Inc | キトサン含有組成物及びキトサンコーティング組成物 |
JP2014139200A (ja) | 2012-12-21 | 2014-07-31 | Nisshin Pharma Inc | 大腸送達カプセル及びその製造方法 |
JP2017532050A (ja) | 2014-12-09 | 2017-11-02 | インターコンチネンタル グレート ブランズ エルエルシー | 腸溶性被覆機能性食品成分及び腸溶性被覆機能性食品成分の製造方法 |
Non-Patent Citations (2)
Title |
---|
MESSAOUD, G. B. et al.,PHYSICO-CHEMICAL PROPERTIES OF ALGINATE/SHELLAC AQUEOUS-CORE CAPSULES: INFLUENCE OF MEMBRANE ARCHITECTURE ON RIBOFLAVIN RELEASE,CARBOHYDRATE POLYMERS,(2016), vol.144,pp.428-437,http://dx.doi.org/10.1016/j.carbpol.2016.02.081 |
MOHAMMAD A. K. Z. et al.,MICROENCAPSULATION OF PROBIOTICS BY CALCIUM ALGINATE-GELATINIZED STARCH WITH CHITOSAN COATING AND EVALUATION OF SURVIVAL IN SIMULATED HUMAN GASTRO-INTESTINAL CONDITION,IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH,2014年,(2014), vol.13,pp.843,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177644/pdf/ijpr-13-843.pdf |
Also Published As
Publication number | Publication date |
---|---|
EP3703514A1 (en) | 2020-09-09 |
WO2019086425A1 (en) | 2019-05-09 |
BR112020008587A2 (pt) | 2020-10-20 |
CN111315237A (zh) | 2020-06-19 |
JP2021501676A (ja) | 2021-01-21 |
US20210177766A1 (en) | 2021-06-17 |
BR112020008194A2 (pt) | 2020-10-06 |
US11602503B2 (en) | 2023-03-14 |
WO2019086427A1 (en) | 2019-05-09 |
CN111315236A (zh) | 2020-06-19 |
JP7331323B2 (ja) | 2023-08-23 |
JP2021501565A (ja) | 2021-01-21 |
KR20200084329A (ko) | 2020-07-10 |
KR20200084330A (ko) | 2020-07-10 |
EP3703515A1 (en) | 2020-09-09 |
US11872316B2 (en) | 2024-01-16 |
US20200352866A1 (en) | 2020-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7331322B2 (ja) | 新規の送達系 | |
US20120301546A1 (en) | Acid-resistant soft gel compositions | |
CN107148266A (zh) | 包含颗粒的制剂 | |
CN108836950B (zh) | 一种蛋白孢粉素口服微胶囊的制备方法 | |
US20220193033A1 (en) | New delivery system for specific water-soluble vitamins | |
CN106794143A (zh) | 诱导饱腹感的方法 | |
Muvva et al. | Modified pectins for colon-specific drug delivery | |
CN105534950A (zh) | 一种饲料用吉他霉素固体微囊的生产方法 | |
JP7065454B2 (ja) | 反応安定性向上微粒子混合食品 | |
US20220226254A1 (en) | New delivery system for fat soluble vitamins | |
Soares et al. | Study of a delayed-release system for hard and soft capsules coated with eudragit® s100 acrylic polymers | |
US20220192998A1 (en) | New delivery system for polyunsaturated fatty acids | |
CN104814958B (zh) | 一种含有阿莫西林的水溶性包被颗粒剂及其制备方法 | |
JP2020203852A (ja) | pH応答性溶出剤、pH応答性溶出剤被覆造粒物、食品および医薬品 | |
JP2007505129A (ja) | (−)−ヒドロキシクエン酸の腸溶性送達物 | |
EP1346723A1 (en) | Multiparticulate enteric coated and multiparticulate enteric coated prolonged release formulations containing NADH | |
PT2842550T (pt) | Preparações compreendendo colagénio de esponja com um perfil de libertação in vivo definido em especial no cólon, a sua produção e a sua utilização | |
WO2016166060A1 (en) | Oral administration system for the controlled release of active ingredients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210506 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220218 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220322 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220614 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220808 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221115 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230209 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230404 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230711 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230720 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7331322 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |